+1 (208) 254-6996 [email protected]



Don't use plagiarized sources. Get Your Custom Essay on
Research Study Evaluation – Cystic Fibrosis
Just from $13/Page
Order Essay

Prior to beginning work on this assignment, review the multimedia file How to Read a Scholarly Article (Links to an external site.). Using the Research Study Evaluation Template  download, you will critically evaluate the assigned research article. 

The Research Study Evaluation

  • Must include a separate title page with the following:
    • Title of paper
    • Student’s name
    • Course name and number
    • Instructor’s name
    • Date submitted
  • Must use the template provided.
  • Must address the article with critical thought by examining, reflecting, and evaluating the article from an objective viewpoint, using facts to support your argument in the conclusion section of the template.
  • Must properly cite the source article in APA style, as outlined in the Writing Center (Links to an external site.).

Peak Oxygen Uptake and Mortality in Cystic Fibrosis: Systematic Review and Meta-Analysis

Fernanda Maria Vendrusculo, João Paulo Heinzmann-Filho, Juliana Severo da Silva, Margarita Perez Ruiz, and Márcio Vinícius Fagundes Donadio

BACKGROUND: Aerobic fitness, as measured by peak oxygen uptake (V̇O2 peak), correlates with survival in children and adults with cystic fibrosis (CF). We sought to evaluate the effects of V̇O2 peak on mortality rates in subjects with CF. METHODS: An online search in PubMed, Embase, LILACS, and SciELO databases was conducted, and cohort studies that assessed mortality rates after oxygen absorption measurements during a maximal exercise test were included. Data were extracted independently by 2 reviewers. The quality analysis of the selected articles was performed using the Newcastle-Ottawa scale. The main outcome evaluated was the mortality of subjects with CF. Whenever possible, and if appropriate, a random effect meta-analysis was performed. RESULTS: Six cohort studies were included in this systematic review including 551 subjects. Five studies were classified with high methodological quality. Two analyses were carried out to evaluate the influence of V̇O2 peak on mortality. Total difference standardized mean between V̇O2 peak averages in the survival or non-survival groups was �0.606 (95% CI � �0.993 to �0.219, P � .002). In addition, subjects with a lower V̇O2 peak had a significantly higher mortality risk (relative risk 4.896, 95% CI � 1.086 to 22.072, P � .039) in an 8-y follow-up period. CONCLUSION: Low levels of peak oxygen uptake are associated with an increase of 4.9 in the risk of mortality in subjects with CF. This indicates that V̇O2 could be an important follow-up variable to measure, in addition to FEV1. Key words: cystic fibrosis; oxygen consumption; exercise capacity; exercise test; mortality; survival. [Respir Care 2019;64(1):91–98. © 2019 Daedalus Enterprises]


Cystic fibrosis (CF) is a multisystemic genetic disease characterized by progressive loss of lung function and con- sequent limitation of aerobic fitness.1 Although morbidity and mortality are still a major concern in the disease man-

agement, life expectancy is increasing each year with ad- vancement in the diagnosis and treatment; according to data from the Cystic Fibrosis Foundation, the expected median survival in the year 2015 was 41.7 y.2 Thus, as lung function is better maintained and aging of patients increases, other comorbidities rise and there is a growing importance of factors such as the preservation of aerobic fitness status.3

In general, many factors have been associated with a worse prognosis in individuals with CF, among them sex,4

decline in lung function,4-7 number of exacerbations,6,7

nutritional status,7-9 chronic colonization of the airways,10,11

and peak oxygen consumption (V̇O2 peak). 5,11,12 It is known

that the reduction of V̇O2 peak is of multifactorial origin, given that the mechanisms that can limit aerobic fitness include respiratory, cardiovascular, and of peripheral mus- cles.13 Therefore, performance on the cardiopulmonary ex- ercise test (CPET) depends on more than lung function and thus reflects the effects of the disease on other organ systems earlier on,14 although FEV1 has still been cited as

Drs Heinzmann-Filho, Donadio, Vendrusculo, and Ms da Silva, are af- filiated with the Laboratory of Pediatric Physical Activity, Centro Infant, Institute of Biomedical Research, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil. Dr Perez Ruiz is affiliated with the School of Doctoral Studies and Research, Universidad Europea de Madrid, Madrid, Spain.

The authors have disclosed no conflicts of interest.

Correspondence: Márcio Donadio, Laboratory of Pediatric Physical Ac- tivity, Centro Infant, Institute of Biomedical Research, Av. Ipiranga, 6690, 2° andar, Porto Alegre, Rio Grande do Sul, CEP 90610-000, Bra- zil. E-mail: [email protected]

DOI: 10.4187/respcare.06185


the best predictor of mortality in children and adults with CF.4,11,12 Thus, considering only lung function as a disease progression marker may not identify other factors that lead to morbidity and mortality in these subjects. Therefore, aerobic fitness evaluation through CPET seems to be a more comprehensive method.15

CPET is considered the gold standard for evaluating aerobic fitness and has been used not only to follow the evolution of the disease,16 because it evaluates the perfor- mance and interaction of the cardiovascular, respiratory, and metabolic systems,17 but also for the prescription of physical exercise.18 In addition, studies have shown high reproducibility of CPET for young19 and adult20 subjects with CF, demonstrating a coefficient of variation of 9.3% and 6.9%, respectively. Moreover, the recent statement on exercise testing in CF recommends performing CPET in individuals aged � 10 y as an important part of the annual review process.15

Exercise intolerance due to hyperinflation and increased respiratory work caused by airway obstruction may be present as the disease advances,21 although it is increas- ingly common to find some pediatric patients who do not present dynamic hyperinflation during exercise. Aerobic fitness correlates with survival in children12 and adults5,11

with CF. Nixon et al11 was the first to demonstrate that V̇O2 peak (� 45 mL/kg/min) could be a predictor of survival in young individuals. A few years later, this finding was replicated by the study of Pianosi et al,12 which showed that subjects with V̇O2 peak � 82% of predicted had a better rate of survival.

Thus, we hypothesized that a low V̇O2 peak was an independent predictor of mortality in individuals with CF. Therefore, we performed a systematic review and quanti- tative meta-analysis of all available studies that reported the effects of peak oxygen consumption on mortality rates in individuals with CF.


This systematic review was performed following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines,22 and data were described according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.23 The protocol of this re- view was registered in the international prospective regis- ter of systematic reviews and was accepted under the num- ber CRD42016045759.

Search Strategy

Studies were identified from the following databases: PubMed, Embase, LILACS, and SciELO. The terms used were (“exercise test” or “exercise testing” or “cardiopul- monary exercise test” or “cardiopulmonary exercise test-

ing” or “peak oxygen uptake” or “maximal oxygen con- sumption” or “exercise tolerance” or “exercise capacity”) and (“mortality” or “survival”) and (“cystic fibrosis”). No filters were used. A manual search was performed on the bibliographic references of the selected articles to search for additional publications that were pertinent to the study purpose. The searches were conducted in March 2017.

Study Selection

Two authors (FMV and JSdS) independently evaluated article titles and abstracts, thereby selecting the studies to be included in the review. Cohort studies of subjects with CF that assessed mortality rates after oxygen uptake mea- surements during a maximal exercise test were included. Articles that did not use variables of the maximal exercise test to predict mortality, articles that assessed the mortality of individuals already on the lung transplant list (because the inclusion of severely ill individuals would potentially bias the analysis), review studies, case studies, experimen- tal models, abstracts, response letters, editorials, and du- plicate publications, as well as those that did not meet inclusion criteria, were excluded after the analysis of the abstract or full text. Disagreements over the inclusion cri- teria of a particular study were discussed and resolved through consensus. A third author (MVFD) evaluated and resolved the discrepancies whenever disagreement or doubts between the 2 authors remained.

Data Extraction

The following data were extracted from each of the selected studies: title, first author’s name, year of publi- cation, country of origin, language of publication, type of study, age of subjects, sample size, type of equipment used, type of protocol used, duration of follow-up, V̇O2 peak, breathing reserve, ventilatory equivalent for peak oxygen consumption (V̇E/V̇O2), and ventilatory equivalent for carbon dioxide production (V̇E/V̇CO2). In addition, data from the variables of the cardiopulmonary exercise test and other variables that could predict the mortality of CF patients were collected. Any discrepancies were resolved by consensus among the researchers. Moreover, whenever appropriate, an attempt to contact authors of the included studies was performed in order to request additional in- formation.

Quality Analysis

The quality analysis of the selected articles was per- formed individually by 2 authors (FMV and JPH-F) using the Newcastle-Ottawa Scale, which assigns a maximum of 9 points to the highest quality studies according to the 3 evaluated parameters: selection (4 points), comparability



(2 points), and outcome (3 points).24 The overall quality of the study was defined as poor (score 0 –3), reasonable (score 4 – 6), or high (score 7–9). The findings were dis- cussed together with a third author (MVFD), and the dis- crepancies or doubts were resolved by consensus.

Synthesis of Data and Statistical Analysis

When possible and appropriate, a randomized meta- analysis of the studies was conducted. The standard dif- ference of the V̇O2 peak averages between the survival and non-survival groups was performed by extracting the av- erage data, sample size, and P value from each study in- cluded in that analysis. The association of high or low V̇O2 peak with mortality was calculated between the survival and non-survival groups by extracting the relative risk and the 95% CI and/or the number of events (death) and the total of participants in each group, using the DerSimonian- Laird randomized model.

Forest plots with the point size reflecting study weight were used to graphically represent the results of meta- analysis. The I2 and Q tests were used to quantify the degree of heterogeneity between the studies. It was not possible to evaluate the bias of publication with the Egg- er’s test due to the small number of studies included in each analysis. All analysis were performed in the compre- hensive meta-analysis software (Biostat, Englewood, New Jersey).


A total of 8,698 articles were found (3,886 in PubMed, 4,787 in EMBASE, and 25 in LILACS). Of these, 2,786 studies were excluded because they were repeated in the database searches, and 5,904 studies were excluded because they did not meet the eligibility criteria of our study. Eight studies were assessed for eligibility, and after analysis of the full text, 2 studies were excluded for in- cluding individuals already on a transplant list.25,26 There- fore, 6 studies were included in this review, and 4 studies were included in the meta-analysis. Figure 1 shows the flow chart of the articles found and the reasons for the exclusion of studies.

The selected articles included a total of 551 subjects, and the sample size of each study varied between 28 and 149 subjects, with ages ranging from 10 to 30.2 y and follow-up time between 2.8 and 8 y (Table 1). Only 2 stud- ies presented CFTR genotype classification, although no separate analyses were performed.9,10 All studies used the cycle ergometer to perform CPET. However, when eval- uating the type of protocol, 3 studies used the Godfrey protocol,9-11 2 performed a ramp protocol,5,27 and 1 study12

used a step increment. The V̇O2 peak, breathing reserve,

V̇E/V̇O2, and V̇E/V̇CO2 data from each article are presented in Table 2.

Regarding the overall methodological quality, 5 of the included studies5,9,11,12,27 were classified as high quality, and two5,11 of these received the maximum score (9 points). On the other hand, only 1 article10 was classified as rea- sonable quality and was assigned 6 points. Table 3 pres- ents the parameters evaluated in the Newcastle-Ottawa Scale.

Table 4 shows the data of significant variables to predict mortality in CF subjects. V̇O2 peak was significant in 5 stud- ies,5,9-12 and breathing reserve was significant in 1 study.9

In the study by Nguyen et al,27 only the arterial-alveolar oxygen gradient was significant. With regard to other vari- ables, FEV1 was significant in 5 studies,5,9,11,12,27 body mass index (BMI) was significant in 2 studies,9,27 and

Records identified through database searching

Duplicates removed 2,786

Records excluded 5,904

Studies included individuals awaiting lung

transplantation: 2

Studies presented only data of total sample: 2

Full-text articles assessed for eligibility


Records screened 5,912

Studies included in systematic review


Studies included in meta-analysis


Studies included in meta-analysis of standard mean

difference 2

Studies included in meta-analysis of

relative risk 2

PubMed: 3,886 Embase: 4,787 LILACS: 25 SciELO: 0

No CPET performed: 2,450 No CF individuals: 1,807 Review papers: 1,163 No access to abstract: 241 Experimental models: 206 No outcomes of interest: 37


Fig. 1. Flow chart. CPET � cardiopulmonary exercise testing; CF � cystic fibrosis.



Pseudomonas cepacia colonization was significant in 1 study.11 To determine the influence of CPET variables on the mortality of subjects with CF, 3 studies9,11,12 used Cox proportional hazards, whereas the other 3 studies used log rank tests,10 multivariate logistic regression,27 and chi- square tests.5


Two different analyses were carried out to evaluate the influence of V̇O2 peak on mortality in subjects with CF, and 2 studies were included in each analysis. Figure 2A shows data from articles reporting differences between averages of V̇O2 peak in the survival and non-survival groups. The I2 analysis did not show heterogeneity be- tween studies (I2 � 0%, P � .84). The total difference standardized mean was �0.606 (CI 95% � �0.993 to �0.219, P � .002), indicating that subjects in the non- survival group had a lower V̇O2 peak compared to survi- vors.

Subjects with a lower V̇O2 peak (� 45 mL/kg/min or � 82% of predicted) were associated with a signifi- cantly higher risk for mortality (relative risk 4.896, 95% CI � 1.086 to 22.072, P � .039). There was a small but not significant heterogeneity in the studies (I2 � 31.56%, P � .23) included in this analysis (Fig. 2B). It was not possible to generate funnel charts in the analysis because of the small number of studies included.


Low aerobic fitness has been reported in individuals with CF and is associated with several factors, including impairment of lung function,28 poor nutritional status,29

low muscle power,28 cardiac dysfunction,30 high level of inflammation,10 and physical deconditioning.28 V̇O2 peak, defined as the peak amount of oxygen that can be trans- ferred and utilized during exercise, is the main parameter in the evaluation of aerobic capacity.18 Our systematic review and meta-analyses demonstrate that subjects with

Table 1. Main Methodological Characteristics of the Studies

Study Country of Origin Type of Cohort Sample Size Age, y* Follow-up, y

Hulzebos et al9 Netherlands Prospective 127 12.7 (11–14) 7.5 Van de Weert-van Leeuwen et al10 Netherlands Prospective 149 13.2 (12–13) 2.8 Nguyen et al27 France Retrospective 51 30.2 (16–67) 3 Pianosi et al12 Canada Prospective 28 10 (7–16) 8† Moorcroft et al5 United Kingdom Retrospective 87 19.8 (15–40) 5 Nixon et al11 United States Prospective 109 17 (7–35) 8

* Mean (range). † Approximate value.

Table 2. Main Results of Cardiopulmonary Exercise Test Variables of the Studies Included in the Systematic Review

Study Baseline V̇O2 Peak Breathing Reserve at Maximum Exercise V̇E/V̇O2 V̇E/V̇CO2

Hulzebos et al9 41.5 � 8.8 mL/kg/min 0.25 � 0.1* 37.4 � 6.8 32.3 � 5.4 93.3 � 17.9% predicted

Van de Weert-van Leeuwen et al10 41.4 � 8.8 mL/kg/min NR NR NR 96.2 � 18.2% predicted

Nguyen et al27 Died: 51.8 � 15.6% predicted 100.1 � 20.5† NR NR Survived: 66.1 � 20.7% predicted 74.5 � 21.3†

Pianosi et al12 41.2 mL/kg/min 0.92‡ NR NR Moorcroft et al5 Died: 53.7% predicted NR Died: 38.7 NR

Survived: 66.6% predicted Survived: 32.4 Nixon et al11 35 mL/kg/min NR NR NR

70% predicted

* 1 � (Peak minute ventilation � maximum voluntary ventilation). † Peak minute ventilation (%) of maximum voluntary ventilation. ‡ Peak minute ventilation/maximum voluntary ventilation. V̇O2 � oxygen uptake NR � not reported V̇E/V̇O2 � ventilatory equivalent for oxygen V̇E/V̇CO2 � ventilatory equivalent for carbon dioxide



lower V̇O2 peak rates (ie, values � 82% of predicted or 45 mL/kg/min) demonstrated a 4.9-fold increased risk for a fatal outcome, indicating that measurement of aerobic fitness could be a tool for prognosis in patients with CF. Furthermore, the difference between means indicated that subjects in the non-survival group had a lower V̇O2 peak compared to the survivors. This association of oxygen consumption with mortality has also been described for individuals with COPD31,32 and chronic heart failure.33,34

To our knowledge, this is the first meta-analysis to eval- uate the association of V̇O2 peak with mortality in subjects with CF.

Nguyen et al27 was the only study included that found no relationship between V̇O2 peak and mortality. They dem- onstrated only that alveolar-arterial gradient for oxygen at peak exercise was significantly associated with mortality. On the other hand, the remaining articles demonstrated an association between V̇O2 peak and mortality. However, other variables, including FEV1 and BMI, were also sig- nificant in predicting mortality. A higher BMI has been associated with an increased likelihood of survival in sub- jects with CF,7-9,35 corroborating the results from Nguyen et al27 and Hulzebos et al.9 Furthermore, FEV1 has been considered the best predictor of mortality in subjects with CF,4,11,12 including those on lung transplant lists.36 Ac- cording to Kerem et al4 individuals with FEV1 � 30% of predicted should be referred for lung transplantation. Moor- croft et al5 showed that, despite the correlation of V̇O2 peak with survival, FEV1 is still the best indicator of prognosis. On the other hand, Rosenthal37 described that lung func- tion between 8 y and 12 y was a poor indicator of the risk of dying or being transplanted. Moreover, Pianosi et al12

demonstrated that the change in V̇O2 peak over time is more useful as a prognostic marker than the commonly used longitudinal decline in FEV1. In addition, abnormal- ities in aerobic fitness in early disease in stable subjects may reflect changes that are not detected with spirometry, given that Dodd et al38 have demonstrated that the corre- lation between thoracic computed tomography abnormal- ities and exercise limitation is stronger than the correlation between spirometry and BMI with exercise limitation. Thus, it is possible that V̇O2 peak is a better prognostic marker early in life than FEV1, considering that CPET is depen- dent on more than lung function and thus reflects the ef- fects of the disease on other organ systems earlier on; however, further studies are needed to directly address this question.

Information obtained through CPET plays an important role in the care and follow-up of patients with CF because of its contribution to prognosis and functional informa- tion.18 Thus, an annual follow-up of V̇O2 peak is relevant to identify individuals at risk for a worsening prognosis,15

as well as those who may benefit from more intense ther- apy,39 considering that aerobic fitness correlates with sur-Ta

bl e

3. N

ew ca

st le

-O tt

aw a

S ca

le :

M et

ho do

lo gi

ca l

Q ua

li ty

of C

oh or

t S

tu di

es In

cl ud

ed in

th e

S ys

te m

at ic

R ev

ie w

S tu

dy R

ep re

se nt

at iv

en es

s of

th e

E xp

os ed

C oh

or t

S el

ec ti

on of

th e

U ne

xp os

ed C

oh or


A sc

er ta

in m

en t

of E

xp os

ur e‡

O ut

co m

e of

In te

re st

N ot

P re

se nt

at S

ta rt

of S

tu dy

C on

tr ol

fo r

Im po

rt an

t F

ac to

r or

A dd

it io

na l

F ac

to r§

A ss

es sm

en t

of O

ut co

m e

F ol

lo w

-u p

L on

g E

no ug

h fo

r O

ut co

m e

to O

cc ur

F ol

lo w

-u p

of C

oh or

t A

de qu

at e

T ot

al Q

ua li

ty S

co re

H ul

ze bo

s et

al 9

* *

* *

* *

* *

8 V

an de

W ee

rt -v

an L

ee uw

en et

al 1 0

* *

* *

* *


N gu

ye n

et al

2 7

* *

* *

* *

* 7

P ia

no si

et al

1 2

* *

* *

* *

* *

8 M

oo rc

ro ft

et al

5 *

* *

* **

* *

* 9

N ix

on et

al 1 1

* *

* *

** *

* *


A st

ud y

co ul

d be

aw ar

de d

a m

ax im

um of

1 st

ar (*

) fo

r ea

ch it

em ex

ce pt

fo r

th e

it em

C on

tr ol

fo r

Im po

rt an

t F

ac to

r or

A dd

it io

na l

F ac

to r.

T he

de fi

ni ti

on /e

xp la

na ti

on of

ea ch

co lu

m n

of th

e N

ew ca

st le

-O tt

aw a

S ca

le is

av ai

la bl

e on

li ne

.2 4

† T

he ca

te go

ry do

es no

t ap

pl y

to th

e ex

po su

re in

ve st

ig at

ed in

th e

sy st

em at

ic re

vi ew

. T

hu s,

al l

st ud

ie s

w er

e eq

ua ll

y gr

ad ed

. ‡

D es

cr ip

ti on

of th

e er

go m

et er

an d

th e

pr ot

oc ol

us ed

. §

A m

ax im

um of

2 st

ar s

co ul

d be

aw ar

de d

in th

is it

em .

S tu

di es

re ce

iv in

g 1

st ar

: T

es te

d F


1 on

a m

ul ti

va ri

at e,

un iv

ar ia

te or

m ix

ed m

od el

an al

ys is

; 2

st ar

s: te

st ed

3 of

th e

4 va

ri ab

le s

(a ge

, bo

dy m

as s

in de

x, se

x, an

d ch

ro ni

c co

lo ni

za ti

on by

P se

u d o m

o n a s

a er

u g in

o sa

or B

u rk

h o ld

er ia

ce p a ci

a )

in th

e m

od el

s de

sc ri

be d

pr ev

io us

ly .

� C

oh or

t st

ud ie

s w

it h

a m

ea n/

m ed

ia n

fo ll

ow -u

p ti

m e

� 5

y (6

0 m

on th

s) re

ce iv

ed 1

st ar

; if

th e

m ea

n fo

ll ow

-u p

ti m

e w

as no

t cl

ea rl

y in

di ca

te d,

th en

th e

st ud

y re

ce iv

ed no

st ar




vival in children12 and adults5,11 with CF. In addition, it is well-established that exercise increases V̇O2 peak, indicat- ing its importance as a therapeutic tool that could influ- ence prognosis.40

The studies included in this systematic review and meta- analysis showed variation in follow-up time, ranging from 2.8 y to 8 y. Considering that these are studies to evaluate mortality, a short follow-up time may be considered as a limitation because it could influence this outcome. In ad- dition, it is already known that the evolution of CF is characterized by a decline in lung function and exercise

limitation,1 highlighting the role of long-term follow-up periods in the evaluation of mortality rates.

As for the reported variables of CPET, the included studies showed a large variability, which prevented us from including some articles in certain analyses and to evaluate the influence of other variables such as ventila- tory reserve data, V̇E/V̇O2, and V̇E/V̇CO2. A high breathing reserve index at the lactate threshold represents a reduc- tion of pulmonary mechanical reserve and was already reported as a predictor of mortality in individuals with CF waiting for lung transplantation.25 In addition, V̇E/V̇O2 mea-

Table 4. Variables Used as Mortality Predictors in Patients with Cystic Fibrosis

Study Exercise Capacity Variables Other Variables

Hulzebos et al9 V̇O2/kg (% predicted): 2.96 (1.06–8.23)* FEV1%: 17.84 (4.02–79.08)* Breathing reserve: 3.35 (1.19–9.48)* BMI: 8.1 (2.93–22.51)*

Van de Weert-van Leeuwen et al10

Maximum V̇O2/kg (% predicted) � 80: 96.3% mortality† NA Maximum V̇O2/kg (% predicted) � 80: 80.0% mortality

Nguyen et al27 Peak P(A-a)O2: 0.794 (0.668–0.943, P � .009)‡ FEV1%: 1.015 (0.904–1.139, P � .80)‡ Body mass index: 1.8 (1.1–2.9, P � .03)‡

Pianosi et al12 Peak V̇O2 intercept: 0.910 (0.816–1.014, P � .09)* FEV1 intercept: 0.915 (0.868–0.964, P � .001)* Peak V̇O2 slope: 0.048 (0.005–0.430, P � .007)* FEV1 slope: 0.008 (0.0003–0.210, P � .004)*

Moorcroft et al5 Peak V̇O2 (cut-off 56%): 64% sensitivity and 72% specificity

FEV1 (cut-off 55%): 91% sensitivity and 74% specificity

Nixon et al11 Peak V̇O2 % (� 58 vs � 82): 3.2 (1.2–8.6, P � .02)§ FEV1% (� 50 vs � 65): 1.1 (0.4–2.7, P � .83)§ Pseudomonas cepacia (present vs absent):

5.0 (2.6–9.5, P � .001)§

* Hazard ratio (95% CI). † P � .02. ‡ Odds ratio (95% CI). § Relative risk (95% CI). V̇O2 � oxygen uptake P(A-a)O2 � alveolar-arterial oxygen difference BMI � body mass index

Study or Subgroup

Nguyen et al27

Moorcroft et al5

Total (95% CI)

Heterogeneity: Tau2 = 0; Chi2 = 0.039, df = 1 (P = .84); I2 = 0% Test for overall effect: Z = −3.071 (P = .002)

















−0.656 (−1.284 to −0.028)

−0.575 (−1.066 to −0.085)

−0.606 (−0.993 to −0.219)



















19.615 (1,229 to 313,077)

3.20 (1.195 to 8.567)

4.896 (1.086 to 22.072)

Study or Subgroup

Pianosi et al12

Nixon et al11

Total (95% CI)

Total events Heterogeneity: Tau2 = 0.519; Chi2 = 1.461, df = 1 (P = .23); I2 = 31.56% Test for overall effect: Z = 2.068 (P = .039)

Non survivorA


Non survivor

Means Total Means P Weight, %Total Survivor


IV, Random, 95% CI Std. Mean Difference

High peak VO2 . .

Events EventsTotal P Weight, %Total Low–moderate peak VO2

High peak VO2 . .

Low–moderate peak VO2

M-H, Random, 95% CI Risk Relative

M-H, Random, 95% CI Risk Relative

IV, Random, 95% CI Std. Mean Difference

−1.00 −0.50 0.50

0.01 0.1 1 10 100

0 1.00

Fig. 2. Meta-analysis of studies that reported mean difference in V̇O2 peak between survival or non-survival groups (A) and the association (relative risk, 95% CI) of V̇O2 peak (high vs. low–moderate) with mortality (B). Low V̇O2 peak was considered when � 45 mL/kg/min or 82% of predicted.



surement has also been shown to be important in predict- ing mortality.5,9 Despite the relevance of the analyzed vari- ables, it is important to recognize that CPET is not widely available in CF centers and requires specific equipment and expert personnel to perform and interpret the test. On the other hand, increasing life expectancy and new thera- peutic options are changing the clinical presentation of CF, and markers such as lung function are better maintained over time, highlighting the importance of other factors such as aerobic fitness. Thus, studies designed to evaluate the prognostic value of CPET as compared to nutritional status, lung function, and other exercise tests are needed to further understand the role of aerobic fitness as a disease progression marker in CF.

Regarding the methodological quality of the studies in- cluded, in general, a high quality was found because only 1 study10 presented a reasonable classification according to the Newcastle-Ottawa Scale, which strengthens our sys- tematic review and meta-analysis. In addition, the I2 test in the analysis of the difference between means did not show heterogeneity, and the relative risk analysis showed a low heterogeneity among the included studies, which may con- firm the power of the analysis presented, despite the small number of articles.

One of the main limitations of this study is the small number of articles included in each analysis and the vari- ability of the parameters evaluated. Due to the different presentations of data, only 2 articles were included in each of the analyses. Therefore, it was not possible to perform a funnel chart to evaluate publication bias of the studies. A short follow-up period, especially for a population of young children and adolescents, may also be considered a limi- tation in the evaluation of mortality. Two studies9,10 in- cluded subjects from the same CF center and with similar characteristics, which may include some shared members of a cohort. In addition, the lack of response when we tried to contact the authors of some of the studies9-12 to request additional V̇O2 peak information distinguished between sur- vivors and non-survivors may be considered a limitation of present study.


This systematic review and meta-analysis showed that a low level of peak oxygen uptake is associated with higher mortality in CF, as subjects with reduced V̇O2 peak had a 4.9-fold increased risk for a fatal outcome. This indicates that V̇O2 peak may be an important follow-up variable to measure in addition to FEV1, although data from our anal- yses should be interpreted with caution due to the small number of studies included. Moreover, comparisons be- tween aerobic capacity variables, FEV1, and BMI as mor- tality predictors in CF need to be further explored in future studies.


1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and manage- ment of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168(8):918-951.

2. Cystic Fibrosis Foundation Patient Registry, 2015 Annual Data Re- port. Available at https://www.cff.org/Our-Research/CF-Patient- Registry/2015-Patient-Registry-Annual-Data-Report.pdf Accessed Feb 20, 2017.

3. Currie S, Greenwood K, Weber L, Khakee H, Legasto M, Tullis E, et al. Physical activity levels in individuals with cystic fibrosis- related diabetes. Physiother Can 2017;69(2):171-177.

4. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326(18): 1187-1191.

5. Moorcroft AJ, Dodd ME, Webb AK. Exercise testing and prognosis in adult cystic fibrosis. Thorax 1997;52(3):291-293.

6. Buzzetti R, Alicandro G, Minicucci L, Notarnicola S, Furnari ML, Giordano G, et al. Validation of a predictive survival model in Italian patients with cystic fibrosis. J Cyst Fibros 2012;11(1):24-29.

7. Liou TG, Adler FR, FitzSimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153(4):345-352.

8. Fogarty AW, Britton J, Clayton A, Smyth AR. Are measures of body habitus associated with mortality in cystic fibrosis? Chest 2012; 142(3):712-717.

9. Hulzebos EH, Bomhof-Roordink H, van de Weert-van Leeuwen PB, Twisk JW, Arets HG, van der Ent CK, Takken T. Prediction of mortality in adolescents with cystic fibrosis. Med Sci Sports Exerc 2014;46(11):2047-2052.

10. Van de Weert-van Leeuwen P, Slieker M, Hulzebos H, Kruitwagen C, van der Ent C, Arets H. Chronic infection and inflammation affect exercise capacity in cystic fibrosis. Eur Respir J 2012;39(4):893-898.

11. Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 1992;327(25):1785-1788.

12. Pianosi P, Leblanc J, Almudevar A. Peak oxygen uptake and mor- tality in children with cystic fibrosis. Thorax 2005;60(1):50-54.

13. Troosters T, Langer D, Vrijsen B, Segers J, Wouters K, Janssens W, et al. Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis. Eur Respir J 2009;33(1):99- 106.

14. American Thoracic Society. ATS/ACCP statement on cardiopulmo- nary exercise testing. Am J Respir Crit Care Med 2003;167(2):211- 217.

15. Hebestreit H, Arets HG, Aurora P, Boas S, Cerny F, Hulzebos EH, et al. Statement on exercise testing in cystic fibrosis. Respiration 2015;90(4):332-351.

16. Pianosi P, LeBlanc J, Almudevar A. Relationship between FEV1 and peak oxygen uptake in children with cystic fibrosis. Pediatr Pul- monol 2005;40(4):324-329.

17. Savi D, Di Paolo M, Simmonds N, Onorati P, Internullo M, Quattrucci S, et al. Relationship between daily physical activity and aerobic fitness in adults with cystic fibrosis. BMC Pulm Med 2015;15(1):59.

18. Ferrazza A, Martolini D, Valli G, Palange P. Cardiopulmonary ex- ercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration 2009;77(1):3-17.

19. Saynor ZL, Barker AR, Oades PJ, Williams CA. Reproducibility of maximal cardiopulmonary exercise testing for young cystic fibrosis patients. J Cyst Fibros 2013;12(6):644-650.

20. McKone E, Barry S, FitzGerald M, Gallagher C. Reproducibility of maximal exercise ergometer testing in patients with cystic fibrosis. Chest 1999;116(2):363-368.

21. De Jong W, Van Der Schans C, Mannes G, Van Aalderen W, Grevink R, Koeter G. Relationship between dyspnoea, pulmonry function and



exercise capacity in patients with cystic fibrosis. Respir Med 1997; 91(1):41-46.

22. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000;283(15):2008-2012.

23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: expla- nation and elaboration. Ann Intern Med 2009;151(4):65-94.

24. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non- randomised studies in meta-analyses. Available at http//www.ohri.ca/ programs/clinical_epidemiology/oxford.asp Accessed Mar 27, 2017.

25. Tantisira KG, Systrom DM, Ginns LC. An elevated breathing re- serve index at the lactate threshold is a predictor of mortality in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2002;165(12):1629-1633.

26. Stanchina ML, Tantisira KG, Aquino SL, Wain JC, Ginns LC. As- sociation of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation. J Heart Lung Transplant 2002;21(2):217-225.

27. Nguyen S, Leroy S, Cracowski C, Perez T, Valette M, Neviere R, et al. [Prognostic value of clinical exercise testing in adult patients with cystic fibrosis]. Rev Mal Respir 2010;27(3):219-225.

28. Hebestreit H, Kieser S, Rüdiger S, Schenk T, Junge S, Hebestreit A, et al. Physical activity is independently related to aerobic capacity in cystic fibrosis. Eur Respir J 2006;28(4):734-739.

29. Klijn PH, van der Net J, Kimpen JL, Helders PJ, Van der Ent CK. Longitudinal determinants of peak aerobic performance in children with cystic fibrosis. Chest 2003;124(6):2215-2219.

30. Pianosi P, Pelech A. Stroke volume during exercise in cystic fibrosis. Am J Respir Crit Care Med 1996;153(3):1105-1109.

31. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease:

role of exercise capacity and health status. Am J Respir Crit Care Med 2003;167(4):544-549.

32. Celli BR. Predictors of mortality in COPD. Respir Med 2010;104(6): 773-779.

33. Ingle L, Witte KK, Cleland JG, Clark AL. Combining the ventilatory response to exercise and peak oxygen consumption is no better than peak oxygen consumption alone in predicting mortality in chronic heart failure. Eur J Heart Fail 2008;10(1):85-88.

34. Cicoira M, Davos CH, Francis DP, Doehner W, Zanolla L, France- schini L, et al. Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue. J Card Fail 2004;10(5):421-426.

35. Simmonds NJ, MacNeill SJ, Cullinan P, Hodson ME. Cystic fibrosis and survival to 40 years: a case–control study. Eur Respir J 2010; 36(6):1277-1283.

36. Belkin RA, Henig NR, Singer LG, Chaparro C, Rubenstein RC, Xie SX, et al. Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2006; 173(6):659-666.

37. Rosenthal M. Annual assessment spirometry, plethysmography, and gas transfer in cystic fibrosis: do they predict death or transplanta- tion. Pediatr Pulmonol 2008;43(10):945-952.

38. Dodd JD, Barry SC, Barry RB, Gallagher CG, Skehan SJ, Masterson JB. Thin-section CT in patients with cystic fibrosis: correlation with peak exercise capacity and body mass index 1. Radiology 2006; 240(1):236-245.

39. Javadpour S, Selvadurai H, Wilkes D, Schneiderman-Walker J, Coates A. Does carbon dioxide retention during exercise predict a more rapid decline in FEV1 in cystic fibrosis? Arch Dis Child 2005;90(8): 792-795.

40. Sosa ES, Groeneveld IF, Gonzalez-Saiz L, Lopez-Mojares LM, Vil- la-Asensi JR, Gonzalez MIB, et al. Intrahospital weight and aerobic training in children with cystic fibrosis: a randomized controlled trial. Med Sci Sports Exerc 2012;44(1):2-11.



Copyright of Respiratory Care is the property of Daedalus Enterprises, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder’s express written permission. However, users may print, download, or email articles for individual use.

Research Study Evaluation Template Instructions: Read the assigned article. In the template below, you’ll find key elements of a research study article. Identify those key elements within your article and complete the template. Be sure to reflect the elements of the article as opposed to your opinion of the article. In the conclusion, you will critically evaluate the effectiveness of the article. Save the document on your computer or to an external hard drive, and when you are finished, submit it to Waypoint for grading.

Name: Date: Instructor’s name: Course name/number:

1. Identify the research topic. 2. Identify the author’s summary of the need for the research. 3. Identify and describe variables in the study. 4. Identify the research question(s) and hypotheses. 5. Identify the research design of the study. 6. Identify any limitations on the study. 7. Identify the sample or population.

8. Describe how the sample was obtained. 9. Analyze the data used. 10. Describe whether the data is primary or secondary. 11. Determine the statistics used to analyze the data. 12. Summarize the findings of the study. 13. Identify the answers to the research questions.

14. Determine whether or not the hypothesis(es) was proved or disproved. 15. Summarize the evidence produced by the study to support the findings.

Conclusion In one to two paragraphs, determine whether or not the study was clearly written. Explain whether or not methods used were comprehensible. Determine whether or not the study adequately addressed the strengths, weaknesses, and limitations of the study. Suggest future research directions. As part of the suggested future research, include additional forms of statistical analyses. APA Citation of the Article

Order your essay today and save 10% with the discount code ESSAYHELP